Raju Mohan, Ventyx Biosciences CEO

Ven­tyx sprints to Wall Street less than a year af­ter emerg­ing from stealth

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It took sev­en months from ex­it­ing “qui­et mode” for Ven­tyx Bio­sciences to land its very own stock tick­er, rais­ing $165 mil­lion in ven­ture funds along the way.

Now, af­ter pric­ing a mas­sive $151.5 mil­lion IPO, the Encini­tas, CA-based biotech is gun­ning for Phase II.

Ven­tyx priced close to 9.5 mil­lion shares at $16 apiece on Wednes­day, the mid­point of its $15 to $17 range. CEO Ra­ju Mo­han filed the S-1 pa­pers at the end of Sep­tem­ber, just over a week af­ter un­veil­ing a $114 mil­lion Se­ries B round. He pen­ciled in the stan­dard fig­ure of $100 mil­lion at first, like­ly know­ing that in the last year, it’s been com­mon for biotechs to raise much more than those ini­tial es­ti­mates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.